Question special
Faculty Member

In this trial, 60% of patients had provoked clots, similar to real world prevalence of DVTs(compared to 5% in amplify-ext). Guidelines do not recommend any extended therapy for these patients.

1. Do you think the provoked patients included we're perceived as risky provoked patients by their referring providers?

2. How do you think this affects the results and the comparison to apixaban?